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Abstract
Background: There is limited data on the epidemiology of Immune Reconstitution Inflammatory Syndrome (IRIS) in rural
sub-Saharan Africa. A prospective observational cohort study was conducted to assess the incidence, clinical characteristics,
outcome and predictors of IRIS in rural Mozambique.
Methods: One hundred and thirty-six consecutive antiretroviral treatment (ART)-naı¨ve HIV-1-infected patients initiating ART
at the Manhic¸a district hospital were prospectively followed for development of IRIS over 16 months. Survival analysis by
Cox regression was performed to identify pre-ART predictors of IRIS development.
Results: Thirty-six patients developed IRIS [26.5%, incidence rate 3.1 cases/100 persons-month of ART (95% CI 2.2–4.3)].
Median time to IRIS onset was 62 days from ART initiation (IQR 35.5–93.5). Twenty-five cases (69.4%) were ‘‘unmasking’’, 10
(27.8%) were ‘‘paradoxical’’, and 1 (2.8%) developed a paradoxical worsening followed by the unmasking of another
condition. Systemic OI (OI-IRIS) accounted for 47% (17/36) of IRIS cases, predominantly of KS (8 cases) and TB (6 cases) IRIS.
Mucocutaneous IRIS manifestations (MC-IRIS) accounted for 53% (19/36) of IRIS events, mostly tinea (9 cases) and herpes
simplex infection (3 cases). Multivariate analysis identified two independent predictors of IRIS development: pre-ART CD4
count ,50 cells/ml (HR 2.3, 95% CI 1.19–4.44, p = 0.01) and body mass index (BMI) ,18.5 (HR 2.15, 95% CI 1.07–4.3, p = 0.03).
The pre-cART proportion of activated T-cells, as well as the immunologic and virologic response to ART were not associated
with IRIS development. All patients continued on ART, 7 (19.4%) required hospitalization and there were 3 deaths (8.3%)
attributable to IRIS.
Conclusions: IRIS is common in patients initiating ART in rural Mozambique. Pre-ART CD4 counts and BMI can easily be
assessed at ART initiation in rural sub-Saharan Africa to identify patients at high risk of IRIS, for whom close supervision is
warranted.
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Introduction
Combined Antiretroviral therapy (cART) has led to dramatic
declines in the morbidity and mortality secondary to HIV
infection and AIDS-associated opportunistic illness (OI) [1,2].
However, some patients initiating cART experience clinical
deterioration, which has been called the immune reconstitution
inflammatory syndrome (IRIS). IRIS is observed in patients who
demonstrate a good response to ART but experience a
paradoxical clinical worsening. In these patients, the rapid
restoration of functionally active antigen-specific cells after ART
is hypothesized to initially lead to an immunopathologic rather
than protective effect, resulting in worsening of a known condition
(‘‘paradoxical’’ IRIS) or a presentation of previously unrecognized
OI (‘‘unmasking’’ IRIS) [3]. IRIS has been related to a variety of
etiologies, including tuberculosis (TB), non-tuberculous mycobac-
teria, cryptococcus, herpesviruses, and Kaposi’s Sarcoma (KS)
[3,4,5,6].
Previous studies, have reported an IRIS incidence of 8–32% of
patients initiating ART [7,8,9,10,11]. A recent meta-analysis
found IRIS incidence to be of 16.1% of unselected patients
starting cART, varying according to the provoking pathogen [12].
Disparities may be explained by differences in OIs investigated,
IRIS case definitions, and study populations. Remarkably, few
studies have characterized IRIS in sub-Saharan Africa (SSA),
where a high burden of IRIS related-OI exists. In a prospective
study conducted in South Africa, 10.4% of patients initiating
cART developed IRIS, mostly associated with TB, dermatological
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manifestations, varicella zoster infection, herpes simplex infection,
and Cryptococcal meningitis [10]. More studies are needed to
better characterize IRIS in rural SSA.
Four major risk factors for IRIS development have been
identified: Low CD4 count at cART initiation [7,8,10,11]; (ii)
robustness of immunologic and virologic response to cART [9,13];
(iii) high antigenic burden of an OI at cART initiation [14], and
(iv) early initiation of cART after some OI, particularly TB [5,9].
Substantial heterogeneity exists across studies, but the predictor
most consistently associated with IRIS development is a low pre-
cART CD4 count.
We conducted a prospective cohort study in a rural area of
Mozambique aimed at assessing the incidence, clinical character-
istics, outcome and predictors of IRIS in this area.
Methods
Study population and Ethics statement
This study was conducted from April 2006 through May 2008
at the Manhic¸a District Hospital (MDH), in southern Mozam-
bique. All HIV-1 positive non-pregnant adults living in the study
area, attending the HIV/AIDS voluntary counselling and testing
services at the MDH, and meeting cART criteria were invited to
participate. CART criteria and regimens used are specified
elsewhere [15].
All patients gave written informed consent, and the study
protocol was approved by the Mozambican National Bioethics
Committee (ref. 44/CNBS/06) and the Hospital Clinic of
Barcelona Ethics Review Committee (ref. CEIC/3158).
Data collection
Visits were scheduled according to the Mozambican Guidelines
and included a pre-treatment assessment and regular assessments
at week 2 and months 4, 10 and 16 after cART initiation. Baseline
serologic assessment of hepatitis B virus (HBV), hepatitis C virus
(HCV), toxoplasma, syphilis, Human T-lymphotropic virus
(HTLV), and human herpesvirus-8 (HHV-8) was conducted.
Each scheduled visit included a clinical exam and monitoring of
plasma HIV-1 RNA, CD4, CD8 counts and T-cell activation,
WBC, RBC and platelet counts, and hepatic and renal function.
Passive surveillance for OI was performed throughout the study to
detect potential IRIS cases.
HIV-1 RNA determinations
Plasma HIV-1 viral load was measured using a reverse
transcriptase (RT) polymerase chain reaction (PCR) technique
(Amplicor, Roche Monitor-v1.5) from cryopreserved samples. The
lower limit of detection was 400 copies/ml.
Immunology and haematological determinations
CD4 counting was performed after staining fresh whole blood
samples with labelled antibodies: CD4, CD3, CD8, and CD45 in
TruCount tubes (BD Biosciences, California, USA).
To access the percentage of activated CD4 and CD8 T-
lymphocytes, cell staining were performed with CD4, CD38 and
HLA-DR or with CD3, CD8, CD38 and HLA-DR respectively.
Activated T-cells were defined as those CD8 or CD4 T cells
expressing both CD38 and HLA-DR surface markers.
Assessment of baseline co-infections
Determine (Abbott, Illinois, USA) was used for HBV surface
antigen testing. Rapid Plasma Reagin was used for syphilis
screening (HUMAN-diagnostics, Wiesbaden, Germany) and a
treponemal ELISA-Trepanostika (BioMe´rieux, Netherlands) for
confirmation. The remaining serologies were assessed by ELISA:
HCV (HUMAN-diagnostics, Wiesbaden, Germany), HTLV I/II
(Murex, Abbott, Illinois, USA), and HHV-8 (Biotrin, Dublin,
Ireland).
TB cases included those patients smear positive for acid-fast
bacilli or culture positive and those without microbiological
confirmation but with compatible symptoms or signs [16].
IRIS case definition
To define IRIS, we used the criteria proposed by French et al
[5]. IRIS was defined as an abrupt clinical worsening of an existing
condition (‘‘paradoxical’’ IRIS) or new presentation of a previously
unknown OI (‘‘unmasking’’ IRIS) following cART initiation, and
either with a concomitant reduction of at least 1 log10 of HIV-1
RNA levels at the time of IRIS or with 2 of the 3 minor criteria: (1)
increased CD4 count after ART; (2) increase in an immune
response specific to the relevant pathogen; (3) spontaneous
resolution of disease.
Additionally, the exclusion of other causes of worsening was
required: (i) expected clinical course of OI, given cART; (ii) drug
toxicity; (iii) other infection or inflammatory condition; (iv)
withdrawal of previously effective therapy; and (v) failure of
ART: based on either non-adherence or on HIV RNA assessment
[17].
Based on the clinical manifestation, IRIS cases were categorized
as systemic OI-related IRIS (OI-IRIS) and mucocutaneous-IRIS
(MC-IRIS).
Finally, IRIS cases were classified as ‘‘confirmed’’ or ‘‘probable’’
cases. ‘‘Confirmed’’ cases were those who fulfilled IRIS criteria at
the time of the event. ‘‘Probable’’ IRIS cases were those who
fulfilled criteria at the 4-month visit but had incomplete data at the
time of the event, or those for whom competing diagnoses had not
been adequately excluded.
To define all IRIS cases, the agreement of 2 clinicians (E.L and
J.M.M) was required.
Statistical analysis
Baseline and follow-up comparisons between patients who did
and who did not develop IRIS were made using chi-square for
categorical variables, and the Wilcoxon rank-sum test/Kruskal-
Wallis for continuous variables.
The association between pre-cART variables and the time to
develop IRIS was evaluated using survival analysis methodology.
Differences between patients who did and who did not develop
IRIS were tested in a univariate analysis using the Cox
proportional hazards models to compute the hazard ratio
(HR) of developing IRIS and corresponding 95% confidence
interval (CI). Independent risk factors were identified in the
multivariate analysis using a forward selection procedure, using
univariate p,0.12 as inclusion criteria and the likelihood ratio
test to assess the relative fit of the different models. A final
model was derived after assessment for interaction between the
relevant exposures. Kaplan-Meier survival estimates of IRIS
development by the independent predictors identified were
generated and the logrank test was used to compare the different
survival curves.
All statistical analyses were performed using STATA 11
(STATA Corp., Texas, USA).
Results
Cohort patient characteristics
Between April and November 2006, 143 consecutive ART-
naive HIV-1–positive adults with cART criteria were enrolled. Of
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these, 7 patients were lost to follow-up before any medical visit and
were not included in the cohort analysis. Of the 136 patients
included 4 (2.9%) were lost to follow-up between enrolment and
10 months.
Table 1 summarizes the pre-cART characteristics of the 136
patients included in the cohort analysis. All patients were of
African ethnicity, predominantly female (58.8%), and with a
median age at cART initiation of 36 years [Interquartile range
(IQR) 29–45)]. The median baseline CD4 count was 115 cells/ml
(IQR 32.5–183.5), and the median HIV viral load was 5.14 log10
copies/ml (IQR 4.8–5.4, Table 1).
Fourteen patients (10.3%) had a history of previous TB. Forty
(29.4%) were on TB treatment at cART initiation, with a median
time from TB treatment initiation to cART onset of 66.5 days
(IQR 49.5–126). Other pre-cART diagnosis included HBV co-
infection (18/136, 13.2%), syphilis (16/136, 11.8%), KS (13/136,
9.6%), HCV co-infection (8/136, 5.9%), and cerebral cryptococ-
cosis (2/136, 1.5%).
Table 1. Summary of patient characteristics before cART initiation according to the development of IRIS.
Total patients
(n = 136)
IRIS patients
(n = 36)
Non-IRIS patients
(n = 100) P value
Age, median (IQR) 36
(29–45)
34.5
(29–39.5)
37.5
(29.5–45)
0.17
18–30 years, n(%) 41 (30.5) 13 (36.1) 28 (28)
31–40 years, n(%) 47 (34.6) 15 (41.7) 32 (32)
.40 years, n(%) 48 (35.3) 8 (22.2) 40 (40)
Gender, n(%)
Female 80 (58.8) 21 (58.3) 59 (59) 0.94
Male 56 (41.2) 15 (41.7) 41 (41)
African ethnicity, n(%) 136 (100) 36 (100) 100 (100)
Body Mass index
Median (IQR) 21 (18-6–22.9) 20 (18–21.3) 21.3 (19–23) 0.009
,18.5, n(%) 32 (23.5) 12 (33.3) 20 (20) 0.1
Karnofsky Performance Scale .80%,
n(%)
115 (84.6) 28 (77.8) 87 (87) 0.19
HIV WHO stagea
I–II 30 (22.6) 5 (13.9) 25 (25.8) 0.145
III–IV 103 (77.4) 31 (86.1) 72 (74.2)
CD4 lymphocyte counts
Median cells/mL (IQR)b 115
(32.5–183.5)
68
(20.5–156.5)
130.5
(42.5–204.5)
0.059
.200 cells/mL, n(%) 31 (22.8) 5 (13.9) 26 (26)
50–200 cells/mL, n(%) 62 (45.6) 14 (38.9) 48 (48)
,50 cells/mL, n (%)b 43 (31.6) 17 (47.2) 26 (26)
CD8 lymphocyte counts
Median cells/mL (IQR) 551 (221.5–1115.5) 618 (193–834.5) 544.5 (221.5–1164) 0.69
Percentage of activated CD4 cells
Median percentage (IQR) 33.4 (23.8–46.3) 32.9 (23.8–51.7) 33.4 (23.8–43.4) 0.88
Percentage of activated CD8 cells
Median percentage (IQR) 66 (57.2–74.9) 65.8 (58.2–74.4) 66.3 (55.2–75.3) 0.64
Percentage of naı¨ve CD4 cells
Median percentage (IQR) 7.5 (2.4–19.3) 9.4 (3.4–20.7) 6.36 (2.4–18.4) 0.56
Plasma HIV viral load
Median log10 copies/ml (IQR) 5.14
(4.8–5.4)
5.17
(4.96–5.4)
5.14
(4.8–5.4)
0.73
.5 log10 copies/ml (IQR) 83 (61) 26 (72.2) 57 (57)
CART regimen, n(%)
d4T/3TC/NVP 85 (62.5) 24 (66.7) 61 (61) 0.38
d4T/3TC/EFV 22 (16.2) 5 (13.9) 17 (17)
AZT/3TC/EFV 23 (16.9) 4 (11.1) 19 (19)
AZT/3TC/NVP 6 (4.4) 3 (8.3) 3 (3)
*Baseline WHO stage: 3 missing values; d4T: Stavudine; 3TC: Lamivudine; NVP: nevirapine; EFV: efavirenz.
doi:10.1371/journal.pone.0016946.t001
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All patients received cART, nevirapine-based for 91 patients
(66.9%), and efavirenz-based for 45 patients (33.1%).
Incidence and clinical description of IRIS cases
The 136 patients contributed 1151.7 person-month (p-m) of
follow-up, with a median time of 9.8 months (IQR 2.3–16.1).
Thirty-six patients (26.5%) developed IRIS [incidence rate 3.1
cases/100 p-m of ART (95% CI 2.2–4.3)]. Of these, 30 (83.3%)
were ‘‘confirmed’’, and 6 (16.7%) were ‘‘probable’’ cases. The
median time to IRIS development was 62 days (IQR 35.5–93.5)
from cART initiation. Twenty-five cases (69.4%) were ‘‘unmask-
ing’’, 10 (27.8%) were ‘‘paradoxical’’, and 1 (2.8%) developed a
paradoxical worsening followed by the unmasking of another
condition. Diagnosis included systemic OI (OI-IRIS) in 17 (47.3%)
cases [KS (8/36, 22.2%), TB (6/36, 16.7%) including 2 patient
with both KS-IRIS and TB-IRIS, interstitial pneumonitis of
unknown etiology (2/36, 5.6%), Pneumocystis jirovecii pneumonia (1/
36, 2.8%), cervical cancer (1/36, 2.8%), and Strongyloides stercoralis
diarrhea (1/36, 2.8%)] and muco-cutaneous manifestations (MC-
IRIS) in the remaining 19 patients (52.7%) [Tinea (9/36, 25%),
herpes simplex infection (3/36, 8.3%), genital warts (2/36, 5.6%),
varicella zoster infection (2/36, 5.6%), recurrent oral aphtosis
ulcers (1/36, 2.8%), impetigo (1/36, 2.8%) and seborrheic
dermatitis (1/36, 2.8%), Table 2].
At the time of IRIS development, CD4 counts were available
for 34/36 patients (94.4%) and HIV RNA for 32/36 (88.9%).
Ninety-four percent (32/34) showed an increase in CD4 counts,
and 32/32 showed .1 log10 decrease in HIV RNA compared to
baseline. The median CD4 count was 180 cells/ml (IQR 144–333),
representing a median increase of 104 cells/ml (IQR 49–197) from
pre-cART levels in IRIS patients. The median HIV RNA was
1.12 log10 copies/ml (IQR 0.3–2.7), with a median decrease of 3.2
log10 copies/ml (IQR 1.9–4.7) from pre-cART levels (Table 2).
All patients continued on cART. Four (11.1%) received
corticosteroids and 7 (19.4%) Non-Steroidal Anti-inflammatory
drugs (NSAID). Seven IRIS cases (19.4%) required hospitalization
and 6 died (16.67%), 3 of which were directly attributable to IRIS
[KS-IRIS (patient 7), cervical cancer (patient 16) and interstitial
pneumonitis of unknown etiology (patient 24)]. The other 3 deaths
occurred with a median of 8 weeks (IQR 4–40) after the IRIS
event, and were attributed to a gastroenteritis with severe
dehydration (patient 6), cerebral toxoplasmosis (patient 21), and
to unknown causes (patient 29). The mortality in the non-IRIS
patients was 15% (15/100), similar to the mortality observed in
IRIS patients (p = 0.81).
Risk Factors Associated With IRIS Development
Table 3 shows the incidence rate of IRIS by the different
baseline variables assessed and the univariate and multivariate
analysis of IRIS predictors. Univariate analysis showed an
association between IRIS development and the following pre-
cART variables: Body Mass Index (BMI) ,18.5, Karnofsky Scale
,80%, CD4 counts ,50 cells/ml, and haematocrit ,30%.
Multivariate analysis identified two independent IRIS pre-
cART predictors: CD4 ,50 cells/ml (HR 2.3, 95% CI 1.19–4.44,
p = 0.01) and BMI ,18.5 (HR 2.15, 95% CI 1.07–4.3, p = 0.03).
The combination of both predictors was associated with a greater
than 5-fold hazard of IRIS development compared with the
patients with a CD4 count $50 cells/ml and a BMI $18.5 (HR
5.38, 95% CI 2.14–13.54, p,0.001, Table 3).
Kaplan–Meier estimates for the probability of remaining IRIS
free by these 2 predictors are presented in Figure 1. Nineteen
percent (14/74) of the patients with a pre-cART CD4 count $50
cells/ml and a BMI $18.5 had developed IRIS by 10 months on
cART, whereas all 13 patients with a pre-cART CD4 count,50
cells/ml and a pre-cART BMI,18.5 either had developed IRIS
(7/13, 54%) or had died (6/13, 46%) by month 7 (logrank test
p = 0.01).
A sub-analysis was conducted to determine potential differ-
ences in IRIS predictors by mode of presentation and etiology.
Both a baseline BMI ,18.5 (HR 2.58, 95% CI 1.13–5.89,
p = 0.024) and a pre-cART CD4 count ,50 cells/ml (HR 2.37,
95% CI 1.08–5.21, p = 0.032) independently predicted the
development of ‘‘unmasking’’ IRIS. In contrast, neither of these
factors predicted ‘‘paradoxical’’ IRIS (HR 1.54, 95% CI 0.4–5.5,
p = 0.67 for CD4 count ,50 cells/ml, and HR 1.7, 95% CI 0.4–
6.6, p = 0.43 for BMI,18.5). The only pre-cART variable
associated with the development of ‘‘paradoxical’’ IRIS was a
pre-cART CD4 percentage ,7% (HR 8.6, 95% CI 1.1–68.8,
p = 0.04). Pre-cART CD4 count ,50 cells/ml, HIV RNA .5
log10 copies/ml and BMI ,18.5 were independently associated
with OI-IRIS, but only the BMI showed a trend for predicting
MC-IRIS (Table 4).
Neither a history of previous OI, the variation in CD4 or CD8
at 4 or 10 months, the proportion of naı¨ve CD4 cells, activated
CD4 or CD8 cells, nor the strength of the HIV virologic response
were associated with IRIS development (Table 3).
Discussion
This study describes the incidence and predictors of IRIS
development in a rural sub-Saharan African setting, and suggests
risk factors may differ by the mode of IRIS presentation and etiology.
The patients were representative of the AIDS population in
SSA, with a predominance of young heterosexual women, ART
naı¨ve, and severely immunosupressed at cART initiation [18].
Twenty-six percent of the patients developed IRIS, consistent
with previous studies [8,9,19], however IRIS incidence was higher
than in a similar South African cohort (10.4%) [10]. Whereas this
latter study was conducted in a tertiary hospital with thorough
diagnostic evaluations performed prior to cART onset, our study
was conducted in a district hospital with lower diagnostic facilities.
This might have resulted in a better recognition and treatment of
co-morbidities prior to cART initiation in the South African study
and, as a consequence, a lower rate of IRIS development.
The median time to IRIS onset was 62 days and the majority of
cases occurred within the first 3 months on cART. This concurs
with previous studies [9,10], and is thought to reflect a rapid
restoration of functionally active cells in the first weeks after
cART, leading to a poor regulation of the restored immune system
and a paradoxical clinical worsening [20].
Almost half of our IRIS patients presented with systemic OI (OI-
IRIS) and the remainder with muco-cutaneous manifestations (MC-
IRIS). As expected [3,10,21], TB accounted for a high proportion of
cases among OI-IRIS, whereas the proportion of KS-IRIS was
surprisingly high [22,23]. We have discussed this with more detail
elsewhere [15]. Based on our results, it is plausible that KS-IRIS is
more common than the literature reflects in certain areas of SSA,
likely related to a high HHV-8 prevalence [24].
MC-IRIS has been previously described [25], and accounted
for more than half of the IRIS episodes in our cohort, including
herpes simplex infections, genital warts, herpes zoster, seborrheic
dermatitis, folliculitis and tinea. There are few case reports of tinea
associated with IRIS in western settings [7,26]. However the high
proportion observed in our cohort as well as in a previous South
African study [27] suggests that dermatophytoses-IRIS might be
common in areas with high endemicity of dermatophyte infections
[28,29].
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Approximately 70% of the IRIS cases in our study were
‘‘unmasking’’ IRIS, which may be the most common form observed
in SSA [10,17]. This is likely due to both a higher burden of OI and
to limited diagnostic facilities in rural Africa, and stresses the need
for a careful evaluation of OI prior to cART initiation in these areas.
CART was continued in all IRIS cases and almost a third
required anti-inflammatory treatment. The addition of anti-
inflammatories was not associated with a different outcome,
but the sample size was not powered to draw conclusions
on IRIS treatment. A recent trial has demonstrated a bene-
ficial effect of prednisone in the treatment of ‘‘paradoxical’’
TB-IRIS [30], and further similar studies should evaluate
different therapeutic strategies for other pathogen-specific
IRIS.
Table 2. Clinical Characteristics of IRIS cases (n = 36).
Time to
IRIS
(days)
Baseline CD4
(cells/mL)
Baseline HIV
RNA (log10
copies/ml)
IRIS CD4
(cells/mL)
IRIS HIV
RNA (log10
copies/ml)
Delta CD4
(cells/mL)
Delta HIV
RNA (log10
copies/ml) Diagnosis
IRIS
type Outcome
1 105 136 4.52 184 2.30 48 2.22 Tinea corporis P R
2 36 107 5.27 156 2.30 49 2.97 Genital warts P R
3 78 66 4.94 163 2.30 97 2.64 Genital warts P R
4 36 133 5.11 506 2.30 373 2.81 KS P R
5 21 41 5.40 168 3.08 127 2.32 KS P R
6 41 538 5.03 669 2.30 131 2.73 KS P D (non-IR)
7* 10 233 5.53 N/A N/A N/A N/A KS P D (IR)
8 34 7 4.51 176 2.30 169 2.21 PCP P R
9 96 0 5.21 203 2.69 203 2.52 Strongyloides
stercoralis diarrhea
P R
10 39 13 5.35 333 2.30 320 3.05 TB lymphadenitis P R
11 64 40 5.25 144 2.30 104 2.95 Pulmonary TB/KS P/U R
12 58 236 5.43 247 2.30 11 3.13 Tinea cruris U R
13 24 43 4.99 162 2.30 119 2.69 Genital herpes U R
14* 126 6 5.06 15 N/A 9 N/A Tinea corporis U R
15 11 455 5.35 558 2.88 103 2.47 Genital herpes U R
16 214 31 5.25 255 2.30 224 2.95 Cervical cancer U D (IR)
17 76 112 5.62 215 2.30 103 3.32 Tinea corporis U R
18 185 1 4.53 66 2.30 65 2.23 Genital herpes U R
19 8 165 4.36 199 2.96 34 1.40 Herpes zoster U R
20 82 1 4.63 377 2.30 376 2.33 Tinea faciei U R
21* 61 153 4.61 27 2.76 2126 1.85 Tinea faciei U D (non-IR)
22 87 6 5.43 92 2.30 86 3.13 Herpes Zoster U R
23* 159 182 4.48 363 2.93 181 1.55 Tinea faciei U R
24* 10 110 5.12 N/A N/A N/A N/A Inerstitial
pneumonitis
U D (IR)
25* 48 24 5.01 158 N/A 134 N/A Tinea faciei U R
26 76 17 5.27 45 2.30 28 2.97 Pulmonary TB U R
27 161 71 5.55 77 2.30 6 3.25 KS U R
28 81 401 5.11 714 3.79 313 1.32 Tinea cruris U R
29 21 84 5.27 155 1.40 71 3.87 Impetigo U D (non-IR)
30 197 165 5.13 232 2.30 67 2.83 KS U R
31 39 34 5.34 521 2.30 487 3.04 Inerstitial
pneumonitis
U R
32 64 70 5.54 176 3.83 106 1.71 Recurrent oral aftae U R
33 126 160 4.76 474 2.30 314 2.46 Seborrhoeic
dermatitis
U R
34 91 2 5.03 89 2.30 87 2.73 TB lymphadenitis U R
35 35 24 5.64 21 2.93 23 2.71 Milliary TB/KS U R
36 56 43 5.37 240 1.40 197 3.97 Pleuro-pulmonary
TB
U R
Median 63 68 5 180 2.30 104 3.2
*Probable cases. The rest are confirmed cases; N/A: Not available; P: Paradoxical IRIS; U: Unmasking IRIS; R: Recovery; D: Death; IR: IRIS related death.
doi:10.1371/journal.pone.0016946.t002
Incidence and Predictors of IRIS in Mozambique
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16946
Two independent pre-cART IRIS predictors were identified,
including a CD4 count ,50 cells/ml and a BMI ,18.5. Both
predictors reflect advanced immunosupression, which is accom-
panied by a higher risk of OI, a residual inflammatory state, a
persistent dysfunction of T-cells, and a disruption of homeostatic
regulatory mechanisms [20,31,32]. Low BMI could also reflect
Table 3. Univariate and multivariate analysis by Cox regression of pre-cART factors potentially contributing to IRIS development
(n = 136).
Category n IRIS, n (%) p-m
IRIS rate per 100
p-m, rate (95% CI)
Univariate
HR (95% CI) P value
Multivariate
HR (95% CI) P value
Age (years) 18–30 41 13 31.7) 2.9 4.5 (2.6–7.8) 1
31–40 47 15 (31.2) 3.6 4.1 (2.5–6.8) 0.97 (0.46–2) 0.94
.40 48 8 (16.7) 5 1.6 (0.8–3.2) 0.45 (0.19–1.1) 0.079
Gender Male 56 15 (26.8) 4.3 3.5 (2.1–5.8) 1
Female 80 21(26.2) 7.2 2.9 (1.8–4.5) 0.93 (0.48–1.8) 0.83
BMI $18.5 104 24 (23.1) 9.9 2.4 (1.6–3.6) 1 0.026 1 0.03
,18.5 32 12 (37.5) 1.6 7.4 (4.2–13) 2.21 (1.1–4.4) 2.1 (1.1–4.3)
Karnofsky Scale $80% 115 28 (24.3) 10.7 2.6 (1.8–3.8) 1 0.009
,80% 21 8 (38.1) 0.8 10 (5–20) 2.87 (1.3–6.3)
HIV WHO stagea I–II 30 5 (16.7) 3.1 1.6 (0.7–3.8) 1 0.11
III–IV 103 31 (30.1) 8.4 3.7 (2.6–5.3) 2.15 (0.8–5.5)
Previous OI No 70 17 (24.3) 6.2 2.7 (1.7–4.4) 1 0.45
Yes 66 19 (28.8) 5.3 3.5 (2.3–5.6) 1.28 (0.7–2.5)
CD4 counts
(cells/mL)
$50 93 19 (20.4) 8.7 2.2 (1.4–3.4) 1 0.01 1 0.01
,50 43 17 (39.5) 2.8 6.1 (3.8–9.9) 2.34 (1.21–4.5) 2.3 (1.2–4.4)
CD8 counts
(cells/mL)
,551* 68 16 (23.5) 5.8 2.8 (1.7–4.5) 1 0.6
$551 68 20 (29.4) 5.8 3.5 (2.2–5.4) 1.19 (0.6–2.3)
HIV viral load
(log10 cp/ml)
,5 53 10 (18.9) 5 2 (1.1–3.7) 1 0.12
$5 83 26 (31.3) 6.5 4 (2.7–5.9) 1.79 (0.9–3.7)
Activated CD4
cells (%)
,33.4* 68 18 (26.5) 5.9 3 (1.9–4.8) 1 1
$33.4 68 18 (26.5) 5.6 3.2 (2–5.1) 1 (0.5–1.9)
Activated CD8
cells (%)
,66* 68 19 (27.9) 5.8 3.3 (2.1–5.1) 1 0.7
$66 68 17 (25) 5.7 2.96 (1.8–4.8) 0.9 (0.47–1.7)
Naı¨ve CD4 cells (%) ,7.5 68 15 (22.1) 6 2.5 (1.5–4.1) 1
$7.5 68 21 (30.9) 5.5 3.8 (2.5–5.9) 1.58 (0.81–3.1) 0.18
Total WBC counts
(6103/mL)
$4 92 23 (25) 7.6 3 (2–4.5) 1 0.53
,4 44 13 (29.5) 3.9 3.4 (1.9–5.8) 1.24 (0.63–2.4)
Haematocrit (%) $30 98 21 (21.4) 9.1 2.3 (1.5–3.5) 1 0.016
,30 38 15 (39.5) 2.4 6.3 (3.8–10.4) 2.25 (1.16–4.4)
ALT level (UI/l) ,55 114 28 (24.6) 9.7 2.9 (2–4.2) 1 0.3
,55 22 8 (36.4) 1.8 4.5 (2.3–9.1) 1.5 (0.69–3.3)
cART regimen NVP based 91 27 (29.7) 7.5 3.6 (2.5–5.2) 1 0.3
EFV based 45 9 (20) 4 2.2 (1.2–4.3) 0.67 (0.31–1.42)
CD4 – BMI
(risk category)
1 (high) 74 14 (18.9) 7.5 1.9 (1.1–3.2) 1 0.3
2 19 5 (26.3) 1.3 3.8 (1.6–9.2) 1.67 (0.6–4.63) 0.109
3 30 10 (33.3) 2.4 4.1 (2.2–7.6) 1.94 (0.86–4.37) ,0.001
4 (low) 13 7 (53.8) 0.3 21.9 (10.5–5) 5.38 (2.14–13.5)
aBaseline WHO stage: 3 missing values; n: number of patients; p-m: persons-month of follow-up; HR: Hazard Ratio; CI: Confidence Interval; BMI: Body Mass Index; NVP:
nevirapine; EFV: efavirenz; CD4 – BMI: combination of both independent predictors; Category 1: CD4 $50 cells/mL and BMI $18.5; Category 2: CD4 $50 cells/mL and BMI
,18.5; Category 3: CD4 ,50 cells/mL and BMI $18.5; Category 4: CD4 ,50 cells/mL and BMI ,18; * median.
doi:10.1371/journal.pone.0016946.t003
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unrecognized co-morbidities (such as disseminated TB, Mycobac-
terium avium complex disease, or cryptosporidiosis), and it could
be useful to predict IRIS in rural African settings with low
diagnostic facilities. Interestingly, the combination of both
predictors was associated with a greater than 5-fold hazard of
IRIS compared to the patients with both a CD4 count $50
cells/ml and BMI $18.5. These results suggest than initiation of
cART at higher CD4 counts may result in a lower IRIS
incidence, in addition to a known lower risk of disease
progression [33,34].
Figure 1. Kaplan Meier Survival estimates of IRIS development by the independent predictors identified. Kaplan Meier survival
estimates of immune reconstitution inflammatory syndrome (IRIS) development according to the two independent predictors identified: pre-cART
body mass index (A), pre-cART CD4 count (B), and the combination of both risk factors (C).
doi:10.1371/journal.pone.0016946.g001
Table 4. Multivariate analysis by Cox regression of predictors of IRIS development by etiology.
OI-IRIS (n = 17)
Multivariate HR (95% CI) P value
MC-IRIS (n = 19)
Multivariate HR (95% CI) P value
Body Mass Index
$18.5 1 1
,18.5 2.38 (0.91–6.2) 0.078 2.54 (0.9–7.2) 0.079
CD4 counts
$50 cells/mL 1 1
,50 cells/mL 3.7 (1.4–9.6) 0.007 1.6 (0.6–4.36) 0.34
HIV viral load
,5 log10 copies/ml 1 1
$5 log10 copies/ml 4.58 (1.05–20) 0.043 0.99 (0.39–2.5) 0.99
OI-IRIS: IRIS associated with systemic OI; MC-IRIS: IRIS associated with muco-cutaneous manifestations.
doi:10.1371/journal.pone.0016946.t004
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Our results also suggest that both the pre-cART CD4 count and
BMI could be relevant predictors for OI-IRIS development, but
not for MC-IRIS. They also appear to better predict ‘‘unmasking’’
than ‘‘paradoxical’’ IRIS, where the baseline CD4 percentage
better identified patients at risk. However, these results must be
interpreted with caution, due to the small number of events in
each category.
IRIS is a heterogeneous condition and it is likely that both the
immunopathogenic mechanisms and the predictors of its devel-
opment are determined by the associated pathogen [20].
Interestingly, in a previous sub-analysis of our cohort, high
baseline HIV viral load was identified as an independent predictor
of KS-IRIS [15]. Further studies assessing predictors for pathogen-
specific IRIS are needed.
Neither CD4 nor CD8 activation, as defined in this study, were
found to be risk factors for the development of IRIS. A recent
study has found that pre-cART expression of certain markers such
as PD-1, a marker of T-cell exhaustion, may be associated with
development of IRIS [35]. However, pre-cART CD38 and HLA-
DR expression do not appear to predict IRIS development.
Three deaths were directly attributed to IRIS (8.3%),
highlighting that, although most IRIS cases were mild, IRIS can
be aggressive and hard to manage in resource-poor settings.
All IRIS studies are limited by the lack of confirmatory
diagnostic tests and an internationally accepted IRIS definition.
We used a strict definition and patients were identified
prospectively, only considering previously reported etiologies of
IRIS, and requiring the agreement of two clinicians to establish a
final diagnosis. Other studies have used different definitions, and
in order to compare studies, it is urgent to develop a consensus
definition of IRIS and of pathogen-specific IRIS, such as the one
existing for TB-IRIS [36].
Another limitation of our study is the use of a passive case-
finding approach, possibly leading to an overestimation of the time
to IRIS and to under-recognition of certain self-limited IRIS
presentations. Nevertheless, 89% of the cases were diagnosed in
non-scheduled visits, suggesting an active health-seeking behaviour
in our patients, and the median time to IRIS after cART concurs
with previous data.
In conclusion, with the ART scaling-up in rural SSA, awareness
of IRIS is increasingly important. IRIS clinical spectrum varies
according to the setting and it is thus, important to have case series
and analysis of IRIS predictors from different areas. We have
identified risk factors for IRIS development in a rural African
setting which can easily be assessed at cART initiation. These
predictors can aid in the selection of patients at a higher risk of
IRIS for whom a closer monitoring is warranted. Furthermore,
our findings stress the need for initiating cART at higher CD4
counts in SSA.
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